Cardiovascular Efficacy and Safety of Finerenone: A Meta-Analysis of Randomized Controlled Trials.

ABSTRACT:

Background

Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has emerged as a novel therapeutic option for the management of patients with diabetes, chronic kidney disease, or heart failure. We seek to summarize the evidence on the drug's effectiveness regarding cardiovascular (CV) outcomes.

Methods

We conducted a literature search of Pubmed, Cochrane CENTRAL, Embase, and ClinicalTrials.gov from inception to September 2024. Trials exploring the effects of finerenone on CV outcomes were extracted and analyzed. The results of pooled analyses were presented as risk ratios (RRs) with 95% confidence intervals (CIs).

Results

A total of eight trials, incorporating 21 200 patients, were included. The pooled analysis demonstrated a significant reduction in all-

SUBMITTER: Ahmed M 

PROVIDER: S-EPMC11799767 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature